Cargando…
Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
[Image: see text] Integrase mutations can reduce the effectiveness of the first-generation FDA-approved integrase strand transfer inhibitors (INSTIs), raltegravir (RAL) and elvitegravir (EVG). The second-generation agent, dolutegravir (DTG), has enjoyed considerable clinical success; however, resist...
Autores principales: | Zhao, Xue Zhi, Smith, Steven J., Maskell, Daniel P., Métifiot, Mathieu, Pye, Valerie E., Fesen, Katherine, Marchand, Christophe, Pommier, Yves, Cherepanov, Peter, Hughes, Stephen H., Burke, Terrence R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601359/ https://www.ncbi.nlm.nih.gov/pubmed/28737946 http://dx.doi.org/10.1021/acs.jmedchem.7b00596 |
Ejemplares similares
-
HIV-1 Integrase Strand Transfer Inhibitors
with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016) -
Selectivity for strand-transfer over 3′-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme–DNA interactions in the active site
por: Métifiot, Mathieu, et al.
Publicado: (2016) -
Resistance to Integrase Inhibitors
por: Métifiot, Mathieu, et al.
Publicado: (2010) -
Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing
HIV-1 Integrase Inhibitors Having High Antiviral Potency against
Cells Harboring Raltegravir-Resistant Integrase Mutants
por: Zhao, Xue Zhi, et al.
Publicado: (2014) -
HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence
por: Zhao, Xue Zhi, et al.
Publicado: (2018)